PvPI and CDSCO Integration: New Pharmacovigilance Requirements – biopharmaceutical regulatory affairs PvPI and CDSCO Integration: New Pharmacovigilance Requirements The integration of the Pharmacovigilance Programme of India (PvPI) with the Central Drugs Standard Control Organization (CDSCO) introduces significant advancements in pharmacovigilance, enhancing drug safety regulations. This tutorial comprehensively explores the new requirements and processes, aiding regulatory affairs professionals in navigating the recent changes in biopharmaceutical regulatory affairs. Understanding the Current Landscape of Pharmacovigilance in India The practice of pharmacovigilance in India is pivotal in ensuring the safety and efficacy of pharmaceutical products. The CDSCO, established under the Drugs and Cosmetics Act,…

Form CT-04, CT-05 and CT-11 Updates: Documentation Checklist – pharmacy compliance consulting Form CT-04, CT-05 and CT-11 Updates: Documentation Checklist for Pharmacy Compliance Consulting The Central Drugs Standard Control Organization (CDSCO) has periodically revised its regulatory frameworks to keep pace with the evolving landscape of pharmaceutical compliance. The changes in Forms CT-04, CT-05, and CT-11 are particularly noteworthy, impacting myriad stakeholders including regulatory affairs professionals, industry leaders, and pharmacies. This article provides a thorough tutorial that outlines the necessary documentation checklist pertaining to these updates, focusing on pharmacy compliance consulting, especially for those focused on regulatory affairs in the pharmaceutical…

CDSCO Guidance on Import and Registration of Vaccines – Master’s in Regulatory Affairs and Quality Assurance CDSCO Guidance on Import and Registration of Vaccines The Central Drugs Standard Control Organization (CDSCO) plays a pivotal role in regulating the import and registration of vaccines in India. With global and regional advancements in regulatory affairs influencing practices, understanding the updated guidelines is crucial for professionals engaged in regulatory affairs, particularly those pursuing a master’s in regulatory affairs and quality assurance. This article provides a comprehensive step-by-step tutorial on the CDSCO guidelines, focusing on import and registration processes which are essential for compliance,…

GSR Notifications by MoHFW: What CDSCO Regulates Now – life science compliance consulting GSR Notifications by MoHFW: What CDSCO Regulates Now The Central Drugs Standard Control Organization (CDSCO) in India has been undergoing significant regulatory changes reflective of evolving global health standards and practices, particularly influenced by the Ministry of Health and Family Welfare (MoHFW). This article elucidates the ramifications of the General Safety Rules (GSR) notifications, focusing on what regulatory affairs professionals in the pharmaceutical industry need to know to comply effectively. This tutorial serves as a comprehensive guide for regulatory affairs in pharmaceutical industry professionals and those engaged…

New Approval Process for FDCs and Biologics in India – regulatory affairs in pharmaceutical industry New Approval Process for FDCs and Biologics in India In recent years, the approval process for Fixed-Dose Combinations (FDCs) and biologics in India has undergone significant transformations under the oversight of the Central Drugs Standard Control Organization (CDSCO). These regulatory changes are crucial for professionals working in the pharmaceutical industry, particularly in the fields of regulatory affairs, pharmacovigilance, and clinical operations. This tutorial provides a comprehensive step-by-step guide on the new approval processes, effective January 2025, ensuring that stakeholders are well-informed and adept at navigating…

Changes to PSUR/PBRER Submissions Under CDSCO Rules – regulatory affairs in pharma industry Changes to PSUR/PBRER Submissions Under CDSCO Rules The pharmaceutical industry’s regulatory landscape is continuously evolving, particularly concerning Drug Safety and Regulatory Affairs. As of 2025, significant updates to Periodic Safety Update Reports (PSUR) and Periodic Benefit-Risk Evaluation Reports (PBRER) submissions under the Central Drugs Standard Control Organization (CDSCO) rules in India will take effect. In this comprehensive guide, we will delve into the critical aspects of these changes and outline actionable steps for professionals involved in regulatory affairs in the pharma industry. Understanding PSUR/PBRER Submissions PSURs and…

Timeline Changes in CDSCO Review for NDAs and INDs – pharmaceutical industry regulatory affairs Timeline Changes in CDSCO Review for NDAs and INDs The Central Drugs Standard Control Organization (CDSCO) has undergone significant changes in recent years regarding the review timelines for New Drug Applications (NDAs) and Investigational New Drugs (INDs). Understanding these changes is essential for professionals in the pharmaceutical industry regulatory affairs. This article provides a comprehensive step-by-step guide on the updated regulatory landscape at CDSCO, its implications, and the actions regulatory affairs professionals should take to navigate these modifications effectively. Step 1: Understand the Structure and Functions…

Indian Pharmacopoeia 2025 Revisions and Quality Control Implications – regulatory affairs in pharma industry Indian Pharmacopoeia 2025 Revisions and Quality Control Implications The Indian Pharmacopoeia (IP) is a critical reference for the quality standards of medicines in India, playing a vital role in pharmaceutical regulation and quality assurance. The forthcoming revisions for 2025 introduce notable updates that could impact pharmaceutical companies’ regulatory affairs. This comprehensive guide will provide regulatory affairs professionals in the pharma industry with an in-depth understanding of the revisions, their implications, and the necessary actions to comply with the latest standards. 1. Overview of the Indian Pharmacopoeia…

CDSCO Guidance on Orphan Drug Registration and Incentives – pharmaceutical industry regulatory affairs CDSCO Guidance on Orphan Drug Registration and Incentives Introduction to Orphan Drug Designation in India The Central Drugs Standard Control Organization (CDSCO) plays a crucial role in regulating drug approvals and ensuring the safety and efficacy of pharmaceutical products in India. Among its responsibilities, the CDSCO governs the registration of orphan drugs under specific guidelines aimed at facilitating the development and commercialization of products intended to treat rare diseases. Orphan drugs are classified as those that treat conditions affecting fewer than 200,000 patients in India, thus incentivizing…

CDSCO Expert Committee Recommendations: Latest Trends – regulatory affairs in pharma industry CDSCO Expert Committee Recommendations: Latest Trends in Regulatory Affairs in Pharma Industry The Central Drugs Standard Control Organization (CDSCO) plays a pivotal role in shaping the regulatory landscape for the pharmaceutical industry in India. It is essential for professionals involved in regulatory affairs, pharmacovigilance, and clinical operations to stay abreast of recent trends and recommendations issued by the expert committees within CDSCO. This article provides a comprehensive, step-by-step guide to the latest updates under CDSCO Changes as of 2025, designed specifically for stakeholders in the regulatory affairs in…